论文部分内容阅读
Neurotoxicity associated with cancer chemotherapy is a common and serious clinical problem that limits anticancer drug dosing, impairs patient quality of life and persists long after completion of clinical treatment.A range of neurotoxicity syndromes have been associated with use of anticancer drugs, the most common being peripheral neuropathy.Chemotherapy-induced peripheral neuropathy (CIPN) is a predominantly-sensory chronic neurotoxicity syndrome characterised by distal paraesthesiae and dysesthesiae, sensory ataxia and related functional deficits, and loss of deep tendon reflexes, vibration sense and proprioception.It is a major cumulative dose-limiting toxicity of several anticancer drugs including cisplatin, oxaliplatin, paclitaxel, vincristine, ixabepilone, thalidomide and bortezomib.Studies of CIPN in animal models have the potential for elucidating mechanisms of neurotoxicity, discovering novel strategies for lessening CIPN, and identifying new anticancer drugs and treatment combinations with improved neurotoxicity profiles.